Dossier assessment
Luspatercept (beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Luspatercept (beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Luspatercept (beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with anaemia associated with non-transfusion-dependent beta-thalassaemia
Hint of minor added benefit
Additional information
Federal Joint Committee (G-BA)
2023-09-21 A G-BA decision was published.
Project details
- Project no.
- A23-20
- Commission
- Commission awarded on 27.06.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Haematology
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Luspatercept (beta-thalassaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Luspatercept (myelodysplastic syndromes) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Addendum
Luspatercept (non-transfusion-dependent beta-thalassaemia) - Addendum to Commission A23-20
Status: Commission completed
-
Dossier assessment
Luspatercept (myelodysplastic syndromes) – Benefit assessment according to § 35a Social Code Book V
Status: Commission completed